Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528898) titled 'Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study' on April 1.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Hebei Medical University Fourth Hospital
Condition:
Breast Cancer
Intervention:
Drug: SHR-A1811
Drug: Pertuzumab
Drug: trastuzumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 2026
Target Sample Size: 100
Countries of Recruitment:
China
To know more, visit https://...